论文部分内容阅读
目的探讨Ⅲ期非小细胞肺癌应用同步放化疗综合治疗临床疗效。方法回顾分析本科2005年1月至2008年12月运用综合治疗Ⅲ期非小细胞肺癌45例患者的临床资料。结果放疗结束后,CR、PR、SD、PD率分别为10%,68%,12%,10%。本组15例患者接受2～4个周期后续巩固化疗,余未接受巩固化疗。本组患者1、2、3年生存率分别为62%,32%、15%。本组不良反映较轻,患者可以耐受。结论同步放化疗对不能手术切除的Ⅲ期非小细胞肺癌患者有较好的疗效,且毒副反应小,延长生存期,而且治疗方法安全,患者可以耐受,是目前不能手术切除的Ⅲ期非小细胞肺癌的一种较理想的综合治疗模式,值得临床应用。
Objective To investigate the clinical efficacy of concurrent chemoradiation in the treatment of stage Ⅲ non-small cell lung cancer. Methods The clinical data of 45 patients with stage Ⅲ non-small cell lung cancer undergoing comprehensive treatment from January 2005 to December 2008 were retrospectively analyzed. Results After radiotherapy, the rates of CR, PR, SD and PD were 10%, 68%, 12% and 10%, respectively. The group of 15 patients received 2 to 4 cycles of follow-up consolidation chemotherapy, I did not receive consolidation chemotherapy. The 1, 2, 3-year survival rates of patients in this group were 62%, 32% and 15% respectively. This group of adverse reactions to light, patients can tolerate. Conclusions Simultaneous chemoradiotherapy has a good curative effect on patients with unresectable stage Ⅲ non-small cell lung cancer and has small toxicities and prolonged survival, and the treatment is safe and the patients can tolerate. It is the third stage of unresectable surgery A more ideal combination of non-small cell lung cancer treatment model, it is worth clinical application.